Payne Capital LLC Purchases Shares of 10,540 Merck & Co., Inc. $MRK

Payne Capital LLC acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,540 shares of the company’s stock, valued at approximately $885,000.

Several other large investors have also made changes to their positions in the company. DLD Asset Management LP purchased a new position in shares of Merck & Co., Inc. in the 2nd quarter worth about $2,889,340,000. Norges Bank purchased a new stake in shares of Merck & Co., Inc. during the 2nd quarter worth about $2,858,570,000. Franklin Resources Inc. increased its position in Merck & Co., Inc. by 23.5% during the 2nd quarter. Franklin Resources Inc. now owns 27,032,601 shares of the company’s stock worth $2,139,901,000 after purchasing an additional 5,135,748 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in Merck & Co., Inc. by 35.5% in the second quarter. Arrowstreet Capital Limited Partnership now owns 19,456,096 shares of the company’s stock valued at $1,540,145,000 after buying an additional 5,094,088 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in Merck & Co., Inc. by 9.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 53,865,466 shares of the company’s stock valued at $4,263,991,000 after buying an additional 4,636,183 shares during the period. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $115.87 on Wednesday. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.66 and a quick ratio of 1.44. The company’s fifty day moving average price is $105.66 and its two-hundred day moving average price is $92.48. The firm has a market capitalization of $287.58 billion, a P/E ratio of 15.31, a P/E/G ratio of 1.60 and a beta of 0.28. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $118.46.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.54% and a net margin of 29.63%.The business had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. During the same period in the previous year, the company earned $1.72 earnings per share. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, research analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be issued a dividend of $0.85 per share. The ex-dividend date is Monday, March 16th. This represents a $3.40 annualized dividend and a yield of 2.9%. Merck & Co., Inc.’s payout ratio is currently 44.91%.

Analyst Ratings Changes

MRK has been the subject of several research reports. Wall Street Zen upgraded shares of Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Weiss Ratings restated a “hold (c)” rating on shares of Merck & Co., Inc. in a report on Monday, December 29th. Morgan Stanley upped their price target on shares of Merck & Co., Inc. from $100.00 to $102.00 and gave the stock an “equal weight” rating in a research report on Friday, December 12th. Zacks Research downgraded Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a report on Friday, January 9th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on Merck & Co., Inc. from $110.00 to $111.00 and gave the stock a “hold” rating in a research note on Tuesday, November 18th. Eight research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Hold” and an average target price of $114.53.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Q4 beat — Merck reported Q4 EPS and revenue that topped estimates, driven largely by strong sales of Keytruda and recent product momentum; this supports near-term growth credibility. Merck (MRK) Q4 Earnings and Revenues Beat Estimates
• Neutral Sentiment: Management commentary/earnings call — the earnings call transcript provides detail on pipeline progress and where management expects margin and revenue pressure to land in 2026; useful for gauging whether disappointing guidance is temporary or structural. Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Index/fund positioning — analysis of Merck’s role in S&P 500 funds and broader pharma exposure may influence flows but is less likely to move the stock materially than earnings/guidance. Does Merck & Co. (NYSE:MRK) Maintain Pharma Reach In S&P 500 Fund
• Negative Sentiment: Weak 2026 guidance — Merck guided 2026 revenue to $65.5–$67.0B and adjusted EPS to $5.00–$5.15, both below analyst expectations; management flagged revenue pressure from impending patent expirations (e.g., Januvia) and generic competition. That guidance cut is the primary reason the stock initially sold off. Merck forecasts 2026 sales below estimates on patent losses
• Negative Sentiment: Slower earnings growth expected as Merck increases acquisition and investment spending — coverage highlights that deal activity and near-term margin impacts may slow EPS growth even as the company pursues pipeline and strategic additions. Merck Expects Slower Earnings Growth As It Spends on Acquisitions
• Negative Sentiment: Market reaction and commentary — multiple outlets note the stock dipped after the cautious outlook despite solid Q4 results; analysts and commentators are parsing how much patent losses and 2026 investments will offset Keytruda strength. Merck shares fall as 2026 guidance disappoints despite solid Q4 results

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.